Literature DB >> 23741022

A 10 year surveillance for antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae in community- and hospital-associated intra-abdominal infections in China.

Qiwen Yang1, Hui Zhang1, Yao Wang1, Yingchun Xu1, Minjun Chen1, Robert E Badal2, Hui Wang3, Yuxing Ni4, Yunsong Yu5, Bijie Hu6, Ziyong Sun7, Wenxiang Huang8, Yong Wang9, Anhua Wu10, Xianju Feng11, Kang Liao12, Dingxia Shen13, Zhidong Hu14, Yunzhuo Chu15, Juan Lu16, Bin Cao17, Jianrong Su18, Bingdong Gui19, Qiong Duan20, Shufang Zhang21, Haifeng Shao22, Haishen Kong23, Yunjian Hu24, Huifen Ye25.   

Abstract

The objective of this study was to investigate the susceptibility of hospital-associated (HA) and community-associated (CA) Escherichia coli and Klebsiella pneumoniae isolated from patients with intra-abdominal infections (IAIs) in China. From 2002 to 2011, the minimum inhibitory concentrations (MICs) of 12 antibiotics against 3074 E. coli and 1025 K. pneumoniae from 23 centres located in 16 cities were determined by the broth microdilution method. During the 10 year study period, ertapenem, imipenem, amikacin and piperacillin-tazobactam retained high and stable activity against E. coli and K. pneumoniae isolates regardless of whether their source was HA or CA and regardless of their extended-spectrum beta-lactamase (ESBL) production. However, the susceptibility of E. coli to cephalosporins and ampicillin-sulbactam decreased dramatically during the 10 years, especially for the CA isolates. Fluoroquinolones showed low activity against E. coli. During the whole study period, the ESBL rates for E. coli isolates from IAIs increased from 36.1 % in 2002-2003 to 68.1 % in 2010-2011 (P<0.001). Correspondingly, the ESBL rates in HA isolates increased from 52.2 % in 2002-2003 to 70.0 % in 2010-2011 (P = 0.001), and in CA isolates from 19.1 % in 2002-2003 to 61.6 % in 2010-2011 (P<0.001). The ESBL-positive rate in K. pneumoniae remained between 30.1 and 39.3 % of the total isolates with no significant change during the 10 years. In conclusion, carbapenems retained the highest susceptibility rates against HA and CA E. coli and K. pneumoniae. High prevalence of ESBL in HA E. coli and fast-growing resistance in CA E. coli severely limit the empirical use of the third- and fourth-generation cephalosporins in the therapy of IAIs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23741022     DOI: 10.1099/jmm.0.059816-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  12 in total

1.  Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.

Authors:  Hui Zhang; Qiwen Yang; Kang Liao; Yuxing Ni; Yunsong Yu; Bijie Hu; Ziyong Sun; Wenxiang Huang; Yong Wang; Anhua Wu; Xianju Feng; Yanping Luo; Zhidong Hu; Yunzhuo Chu; Shulan Chen; Bin Cao; Jianrong Su; Bingdong Gui; Qiong Duan; Shufang Zhang; Haifeng Shao; Haishen Kong; Robert E Badal; Yingchun Xu
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

2.  In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases.

Authors:  Mark Estabrook; Brianne Bussell; Susan L Clugston; Karen Bush
Journal:  J Clin Microbiol       Date:  2014-08-20       Impact factor: 5.948

3.  Nationwide high prevalence of CTX-M and an increase of CTX-M-55 in Escherichia coli isolated from patients with community-onset infections in Chinese county hospitals.

Authors:  Jing Zhang; Beiwen Zheng; Lina Zhao; Zeqing Wei; Jinru Ji; Lanjuan Li; Yonghong Xiao
Journal:  BMC Infect Dis       Date:  2014-12-03       Impact factor: 3.090

4.  Lifting the mask: identification of new small molecule inhibitors of uropathogenic Escherichia coli group 2 capsule biogenesis.

Authors:  Carlos C Goller; Mehreen Arshad; James W Noah; Subramaniam Ananthan; Carrie W Evans; N Miranda Nebane; Lynn Rasmussen; Melinda Sosa; Nichole A Tower; E Lucile White; Benjamin Neuenswander; Patrick Porubsky; Brooks E Maki; Steven A Rogers; Frank Schoenen; Patrick C Seed
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

5.  High Prevalence of ESBL-Producing Klebsiella pneumoniae Causing Community-Onset Infections in China.

Authors:  Jing Zhang; Kai Zhou; Beiwen Zheng; Lina Zhao; Ping Shen; Jinru Ji; Zeqing Wei; Lanjuan Li; Jianying Zhou; Yonghong Xiao
Journal:  Front Microbiol       Date:  2016-11-15       Impact factor: 5.640

6.  Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients.

Authors:  Hui Zhang; Qiwen Yang; Kang Liao; Yuxing Ni; Yunsong Yu; Bijie Hu; Ziyong Sun; Wenxiang Huang; Yong Wang; Anhua Wu; Xianju Feng; Yanping Luo; Yunzhuo Chu; Shulan Chen; Bin Cao; Jianrong Su; Qiong Duan; Shufang Zhang; Haifeng Shao; Haishen Kong; Bingdong Gui; Zhidong Hu; Robert Badal; Yingchun Xu
Journal:  BMC Infect Dis       Date:  2017-12-18       Impact factor: 3.090

7.  Carbapenem susceptibilities of Gram-negative pathogens in intra-abdominal and urinary tract infections: updated report of SMART 2015 in China.

Authors:  Hui Zhang; Haishen Kong; Yunsong Yu; Anhua Wu; Qiong Duan; Xiaofeng Jiang; Shufang Zhang; Ziyong Sun; Yuxing Ni; Weiping Wang; Yong Wang; Kang Liao; Huayin Li; Chunxia Yang; Wenxiang Huang; Bingdong Gui; Bin Shan; Robert Badal; Qiwen Yang; Yingchun Xu
Journal:  BMC Infect Dis       Date:  2018-09-29       Impact factor: 3.090

8.  A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China.

Authors:  Yijian Chen; Demei Zhu; Yingyuan Zhang; Yongjie Zhao; Gang Chen; Ping Li; Lihong Xu; Ping Yan; M Anne Hickman; Xiajun Xu; Margaret Tawadrous; Michele Wible
Journal:  Ther Clin Risk Manag       Date:  2018-11-30       Impact factor: 2.423

9.  A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011.

Authors:  Ian Morrissey; Meredith Hackel; Robert Badal; Sam Bouchillon; Stephen Hawser; Douglas Biedenbach
Journal:  Pharmaceuticals (Basel)       Date:  2013-11-01

10.  Sepsis in cancer patients residing in Zimbabwe: spectrum of bacterial and fungal aetiologies and their antimicrobial susceptibility patterns.

Authors:  Frank Chinowaita; Wendy Chaka; Tinashe K Nyazika; Tendai C Maboreke; Emmanuel Tizauone; Prichard Mapondera; Inam Chitsike; Andrew Z Cakana; Rooyen T Mavenyengwa
Journal:  BMC Infect Dis       Date:  2020-02-21       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.